

## Special Issue

# Respiratory Viruses and Antiviral Immunity

### Message from the Guest Editors

The respiratory tract is a major portal of entry for viruses into the body. Various strategies exist to control respiratory virus replication and to limit immune-mediated inflammation and tissue injury. This Special Issue is interested in the contributions of physical and chemical barriers to infection and the various innate immune mechanisms and cell types mediating host responses to virus infections—both innate and adaptive immune responses. Particularly, the features of interest include the protective mechanisms and their pathophysiological implications in viral respiratory infections. We are pleased to invite you to contribute to this Special Issue, which aims to describe, interpret, and analyze the role of the antiviral response in various aspects: as a protective barrier, a mechanism of containment or elimination, and as a basis for the pathophysiology of viral respiratory infections. Within this framework, particular interest is given to questions such as what contributes to viral reinfections and the antiviral response leading to disease and damage and how this understanding can be used to develop therapeutic strategies that include vaccines.

---

### Guest Editors

Dr. Andreu Comas-Garcia

Dr. Sofia Bernal-Silva

Prof. Dr. Maria Grazia Cusi

---

### Deadline for manuscript submissions

31 January 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/216870](https://mdpi.com/si/216870)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).